Literature DB >> 2584547

Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands.

M L Simoons1, J Vos, J G Tijssen, F Vermeer, F W Verheugt, X H Krauss, V M Cats.   

Abstract

Patients (n = 533) who participated in the Interuniversity Cardiology Institute of the Netherlands Trial were followed up for 3 to 7 years. The 5 year survival rate after thrombolytic therapy with intracoronary streptokinase was 81% (269 patients) compared with 71% after conventional therapy (264 patients). The greatest improvement in survival was observed in patients with anterior infarction (81% versus 64% with thrombolytic therapy or conventional therapy, respectively), in those with heart failure on admission or a previous infarction and in those with extensive myocardial ischemia on admission. Left ventricular ejection fraction at the time of hospital discharge was better after thrombolytic therapy. In the hospital survivors, long-term outcome was related to left ventricular function at the time of discharge and, to a lesser extent, to the underlying coronary artery disease. The initial therapy (thrombolysis or conventional) was not an independent additional determinant of long-term survival when left ventricular function and coronary status at the time of hospital discharge were taken into account. Thus, the salutary effects of thrombolytic therapy appear to be the result of myocardial salvage. Reinfarction within 3 years was observed more frequently after thrombolytic therapy, particularly in patients with inferior wall infarction and those with greater than or equal to 90% stenosis of the infarct-related vessel at discharge. Coronary bypass surgery and coronary angioplasty were performed more frequently after thrombolytic therapy than in conventionally treated patients. At 5 years, approximately 40% of patients in both groups had an uneventful course without reinfarction or additional revascularization procedures. These observations demonstrate that the benefits of thrombolytic therapy are maintained throughout 5 years of follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584547     DOI: 10.1016/0735-1097(89)90003-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

1.  Treating myocardial infarction in the post-GUSTO era. A US perspective.

Authors:  D B Mark
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

Review 2.  Treating myocardial infarction in the post-GUSTO era. A European perspective.

Authors:  M J de Boer; F Zijlstra
Journal:  Pharmacoeconomics       Date:  1997-10       Impact factor: 4.981

3.  Cardiology's 10 greatest discoveries of the 20th century.

Authors:  Nirav J Mehta; Ijaz A Khan
Journal:  Tex Heart Inst J       Date:  2002

Review 4.  Role of nuclear cardiac imaging in myocardial infarction: postinfarction risk stratification.

Authors:  John J Mahmarian; Girish Dwivedi; Tultul Lahiri
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

Review 5.  Late potentials as predictors of risk after thrombolytic treatment?

Authors:  G Breithardt; M Borggrefe; U Karbenn
Journal:  Br Heart J       Date:  1990-09

6.  Early prognosis after thrombolysis: value of exercise radionuclide ventriculography performed on anti-ischaemic medication.

Authors:  R Lim; L Dyke; D S Dymond
Journal:  Int J Card Imaging       Date:  1991

7.  Five year outcome after primary coronary intervention for acute ST elevation myocardial infarction: results from a single centre experience.

Authors:  G Parodi; G Memisha; R Valenti; M Trapani; A Migliorini; G M Santoro; D Antoniucci
Journal:  Heart       Date:  2005-04-06       Impact factor: 5.994

8.  Is thrombolytic therapy in acute inferior myocardial infarction really better than conventional treatment?

Authors:  T J Tobé
Journal:  Br Heart J       Date:  1995-02

9.  Risk stratifying patients who survive an acute myocardial infarction.

Authors:  M S Verani
Journal:  J Nucl Cardiol       Date:  1998 Jan-Feb       Impact factor: 5.952

Review 10.  Thrombolytic therapy in the elderly. Pharmacoeconomic considerations.

Authors:  K Ramanathan; C J Ellis; H D White
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.